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Abstract 
As of June 2009, 361 genome-wide association studies (GWAS) had been referenced 
by the HuGE database(1). GWAS require DNA from many thousands of individuals, 
relying on suitable DNA collections. We recently performed a Multiple Sclerosis 
(MS) GWAS where a substantial component of the cases (24 %) had DNA derived 
from saliva. Genotyping was performed on the Illumina genotyping platform using 
the Infinium Hap370CNV DUO microarray. Additionally we genotyped ten 
individuals in duplicate using both saliva and blood derived DNA. The performance 
of blood versus saliva derived DNA was compared using genotyping call rate, which 
reflects both the quantity and quality of genotyping per sample, and the ‘GCScore’, an 
Illumina genotyping quality score, which is a measure of DNA quality. We also 
compared genotype calls and GCScores for the 10 sample pairs. Call rates were 
assessed for each sample individually. For the GWAS samples we compared data 
according to source of DNA and centre of origin. We observed high concordance in 
genotyping quality and quantity between the paired samples, and minimal loss of 
quality and quantity of DNA in the saliva samples in the large GWAS sample with the 
blood samples showing greater variation between centres of origin. This large dataset 
highlights the usefulness of saliva DNA for genotyping, especially in high-density 
SNP microarray studies such as GWAS. 
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Introduction 
Genome wide association studies (GWAS) require the collection of thousands of 
DNA samples to attain sufficient power to map loci responsible for complex diseases. 
DNA for such studies is usually extracted from lymphocytes, with blood collected 
from participants by phlebotomy. A recent study of DNA collection in a Danish nurse 
cohort(2) showed a  markedly greater response rate in recruitment of DNA samples 
from saliva versus blood (72% versus 31% of invited participants returned samples 
respectively). These differences in response stemmed from a variety of issues 
including the commitment required to provide blood by attending a clinic and 
uneasiness, or inability, to undergo phlebotomy. In comparison, saliva collection can 
be done at home, without professional help, and is much less invasive than 
phlebotomy. However, saliva-derived DNA is often contaminated with large amounts 
of bacterial DNA and it is notoriously difficult to determine the relative proportion of 
human DNA. Moreover, different protocols are required for purification and 
quantitation of DNA derived from blood and saliva (3, 4). It is therefore entirely 
plausible that DNA derived from these different sources might show systematic 
differences in genotyping efficiency and accuracy. 
 
We recently performed a Multiple Sclerosis GWAS with 1618 MS cases and 3413 
controls under the auspices of the Australia and New Zealand MS Genetics 
Consortium (ANZgene) (5). Twenty-four percent of MS cases had genotyping 
performed on DNA derived from saliva and the remaining samples were derived from 
blood. The dataset used in the current study consisted of genotypes from these MS 
cases, some of the controls, as well as some samples that were not included in the 
published GWAS. In addition a small dataset consisting of 10 sample duplicates, 
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where both saliva- and blood-derived DNAs were available, was also examined. 
These data were used to investigate the relative genotyping performance of blood and 
saliva derived genomic DNA using the Illumina SNP microarray platform.  
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Materials and Methods 
Genomic DNA (gDNA) from Australian MS cases and controls was extracted from 
whole blood using a variety of standard laboratory approaches including phenol-
chloroform extraction(6), salting out(7) and three different commercial kits from 
Qiagen, Nucleon and Roche, as per manufacturers instructions. gDNA from MS cases 
from New Zealand (NZ) was isolated from saliva self-collected into Oragene DNA 
tubes according to the manufacturer's instructions (DNAgenotek). DNA 
concentrations were assessed using pico green fluorescence, ultraviolet (OD260nm) 
spectrophotometry and/or on an ethidium bromide–stained low-percentage agarose 
gel compared to a high-molecular-weight standard. Because of possible bacterial 
gDNA contamination and difficulty in obtaining reliable pico green and 
spectrophotometry measurements, all saliva DNA samples were estimated and 
assessed for their integrity by agarose gel electrophoresis and using at least one other 
method. Extraction methods, age of samples and time to extraction are summarised by 
study centre in Supplementary Table 1. 
 
Genotyping was performed on the Illumina genotyping platform with the Infinium 
Hap370CNV DUO microarrays for both saliva and blood DNAs using the same 
protocol, at the same facility (Diamantina Institute, Brisbane Queensland), within a 
six-month time frame.  
 
Each genotype call was associated with a genotyping quality score. For the Illumina 
platform this is known as a GCScore, or GenCall Score (see Supplementary Material) 
and ranges from 0 to 1. The GenCall Score is a summary measure consisting of three 
parts: (i) a SNP specific score known as the GenTrain Score which describes the 
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clustering properties of the genotyped SNP, (ii) the fit of the current sample to the 
clustering profile of the SNP, and (iii) the DNAscore which summarises the overall 
DNA quality of the individual. The GenCall Score thus takes into account SNP 
properties, sample DNA properties and SNP-specific sample properties. The score has 
greatest sensitivity in the range of 0.2 to 0.7 with scores >0.7 signalling high quality 
genotypes. Illumina BeadStudio guideline stipulate that the genotype calling software 
determines a call to be a “no-call” if the GCScore<0.15, however the GCScores are 
available for all SNPs, even if the GCScore is below this threshold.  
 
In this analysis we elected to keep all genotyping results regardless of GCScore rather 
than working with a censored distribution. Thus all SNP markers were used for the 
call rate and GCScore analyses (N=353,203 out of a total of 370,405 probes on the 
array), which excludes the copy number variation (CNV) probes (N=17,202) on the 
array.  
 
The call rate of a sample was determined by the number of SNPs with a genotype call 
divided by the total number of SNPs considered. Illumina Beadstudio guidelines 
suggest that samples with a no-call rate> 2% are likely to be of poor quality, so 
samples which failed this threshold were removed from any further analysis.  
 
Paired Sample Study 
Venous blood and saliva were collected from 10 consecutively recruited MS patients 
from study centre Aus9, and the extracted DNAs were genotyped (20 samples in 
total). The samples were assessed individually for call rate and in a paired comparison 
for genotype concordance and GCScore similarity.  
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GWAS Data set 
The original recruitment number of ANZgene samples for the MS study was 2000 
DNA samples. Of these 75 failed preliminary QC requirements. Of the remaining 
1925 samples, 1873 were cases and 52 controls. Stringent QC analysis to remove 
samples and SNPs using additional methods beyond call rate and GCScore thresholds, 
pertaining to the published MS GWAS association analysis, led to the inclusion of 
only 1618 ANZgene cases and 41 controls for the published MS GWAS analysis(5). 
We chose to use the larger dataset involving 1925 samples for the genotyping quality 
analysis in the current study because samples and SNPs rejected for other QC reasons 
than genotyping quality and quantity were still informative for assessment of blood 
and saliva differences. Control data used in the GWAS dataset (N=3370)(5), which 
was provided by the Wellcome Trust Case Control Consortium and the Illumina 
iControl database, were not used in the current study because genotyping quality 
scores were not available. Case/control status was not taken into account in the 
analysis.  
 
Ten centres from Australia, designated as Aus1,..,Aus10, contributed blood derived 
gDNA to the GWAS (Supplementary Table 1). One centre, in New Zealand (NZ), 
sent out Oragene saliva collection kits within NZ to MS cases self-identified to the 
investigators through a national prevalence survey. Saliva samples (95% of mailed 
kits) were returned to the NZ recruitment centre over a 6-month period, and were sent 
to study centre Aus9 where DNA extractions were performed. All samples were 
derived from MS patients with ethnic background verbally verified to be Caucasian. 
All blood and saliva derived DNA samples were genotyped in several genotyping 
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batches over a six-month period. No randomisation for genotype centres or 
case/control status was performed over genotype batches due to time constraints. We 
were unable to investigate genotype batch effects and study centre-specific 
differences between the samples, such as age of sample, due to strong confounding 
between genotype batch and study centre. 
 
The GWAS dataset was assessed for genotype call rate across batches, study centres 
(10 Australian + 1 New Zealand) and DNA source (blood or saliva). The GCScore 
distribution for each individual was summarised using the three quartiles (25th, 50th 
and 75th percentile) of the GCScore distribution and these were averaged within 
relevant pools, either by study centre or by DNA source. The 50th percentile, or 
second quartile, corresponds to the median. The inter-quartile range (IQR) was taken 
as the range of values delimited by the values at the 3rd (upper) and 1st (lower) 
quartiles, respectively. If the data were normally distributed the first and third 
quartiles would correspond to approximately µ-0.7s and µ+ 0.7s where µ is the mean 
and s the standard deviation. 
 
The published MS GWAS analysis(5) included an analysis looking for sample 
stratification that could unduly influence the association analysis. The source of the 
sample stratification is usually ethnic stratification but can also be potentially caused 
by technical factors such as genotyping batches or DNA source. The sample 
stratification analysis was carried out only on the published MS GWAS dataset with 
the software EIGENSTRAT(8) which identifies data clusters using the statistical 
technique of principal component analysis (PCA). There is a strong overlap between 
the set analysed by EIGENSTRAT and the current set of data, as the EIGENSTRAT 
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analysis included 1659 of the 1925 (86 %) of the samples in the current dataset.
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Results 
 
Paired Sample Study 
This study allowed a paired comparison of the blood and saliva derived DNA 
samples, thus removing biological variation and most of the technical variation. The 
blood DNA sample of one of the paired samples had very poor genotyping quality 
with a call rate of 0.59. Therefore, this paired sample was dropped entirely from the 
subsequent statistical analysis leaving nine paired samples. In the remaining nine 
paired samples there was no significant difference in call rates between blood and 
saliva DNA for the complete set of SNPs (353,203 SNPs, one sided paired two-
sample T-test, T8=0.58, p=0.3). We also observed high correlation between GCscores 
between the samples with a median Spearmann’s rank correlation coefficient of 0.82, 
range [0.81,0.83], based on all SNPs, regardless of GCScore (Supplementary material, 
Figures 1-5). There was no difference when SNPs with a GCScore<0.15 were 
excluded. The number of discordant genotype calls in these paired samples was very 
low with a median of 0.0035 % discordant genotypes, with range 0.0007 % to 0.0142 
%, N=9.  
 
GWAS data analysis 
The median SNP call rate (99.82 %, N= 1659) in the GWAS dataset(5) was 
comparable to other published GWAS, and of the original 2000 MS case DNA 
samples genotyped, 75 (3.8%) did not pass the call rate threshold of 98%. No saliva-
derived samples failed the call-rate threshold. The difference in blood and saliva call 
rate threshold failures is highly statistically significant (Z=8.71, p-value<2.2e-16), 
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with saliva derived DNAs much less likely than blood derived DNAs to fail the QC 
threshold in this study.  
 
The median no-call rate of all samples was 0.0019 (call rate of 99.81%, N=1925), for 
blood DNA was 0.0018 and for saliva DNA it was 0.0024 (Figure 2, Supplementary 
Data, Table 1). There was a significantly higher rate of no calls in the saliva samples 
when compared to the blood samples (including only samples with no-call rates 
<0.02, Nsaliva = 399, Nblood = 1526, two sample Wilcoxon-rank sum test=171469, p-
value<2.2e-16).  
 
Blood derived from three centres (Aus1, Aus3 and Aus10) performed poorly in 
comparison with blood and saliva derived DNA from other centres (Supplementary 
Data, Table 2). Aus5 and Aus9 study centre samples also showed additional, intra-
batch effects that could not be explained by other factors such as genotyping batch 
since all samples in these cohorts were either genotyped in the same batch (Aus9) or 
only two batches (Aus5). Further investigation of these data revealed a relationship 
with sample ID suggesting a link to time of collection and possibly systematic 
differences in sample storage and/or processing. 
 
A comparison of GCScores across studies centres also revealed similar patterns of 
genotyping bias as evidenced by differences in no-call rate (Supplementary Table 3). 
The saliva samples had a higher median GCScore than the blood samples, but 
identical quartiles and IQR. The study centres whose samples had lower call rates 
(Aus1, Aus3 and Aus10) often had lower IQR and lower median GCScores indicating 
that they now represent a biased, or much cleaner, sample. In general the GCScore 
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quartiles were very similar across all studies centres but this may reflect the non-
discriminatory nature of the GCScore. 
 
The published GWAS data(5) was subjected to stringent QC including principal 
components analysis (PCA) using EIGENSTRAT(8) software, but this did not 
identify any principal components that clustered with DNA source (data not shown) 
suggesting that saliva derived DNA did not have its own SNP genotyping signature in 
comparison to blood derived DNA.
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Discussion 
DNA samples genotyped in our GWAS were collected through 11 different study 
centres at different times using different extraction methods, and these factors 
appeared to affect genotype data quality more than the source of DNA, although we 
were unable to test this hypothesis specifically. The large size of our study permitted 
averaging over these confounders and a comparison of SNP array-based genotyping 
performance between blood and saliva derived DNA was performed. Our findings 
suggest that saliva collected using the Oragene kit provides good quality genomic 
DNA, which is comparable to blood as a template for SNP genotyping on the Illumina 
platform. Some studies using different genotyping methods such as PCR for a small 
number of polymorphisms(9) support our findings, while others have had little 
success with saliva-derived DNA(10). No other studies have conducted such an 
extensive comparison of genotyping quality using saliva versus blood derived DNA. 
 
Although both Affymetrix and Illumina claim that Oragene saliva DNA works well 
on their SNP arrays, there has been no external validation to date. It is plausible that 
bacterial genomic DNA, which contaminates saliva DNA but not blood DNA, may 
interfere with genotyping quality. However, our results suggest that the Illumina 
platform is robust to this potential confounder. This could be due to processing steps 
and/or the length of the probes on Illumina arrays (50 bp) that may help to overcome 
the effects of bacterial DNA contamination. If the length of the probes were important 
one would expect the Affymetrix system to fare worse than Illumina’s because the 
probes are shorter (25 bp). The Illumina system appears to be quite sensitive to DNA 
concentration and it is recommended that template DNA be standardised to 50 ng/µl 
prior to genotyping. Here we standardised both saliva and blood DNA to the 
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recommended concentration without taking account of the relative proportion of 
human versus bacterial DNA in the saliva DNA samples.  
 
Researchers contemplating genetic studies where it is difficult to derive DNA from 
blood due to disability or aversion to phlebotomy will be reassured that data generated 
from saliva-derived DNA incurs few losses in terms of either genotyping data 
quantity or quality in comparison to blood-derived DNA. It is unknown if our 
findings will translate to other high throughput genotyping platforms such as 
Nimblegen and Affymetrix, although highly variable results were reported for the 
500K Affymetrix platform using un-quantitated saliva-derived DNA(4). Interestingly, 
DNA from whole genome amplified samples also appear to perform well on the 
Illumina platform(11), but genotyping quality and call rate were worse than we 
observed for either saliva or blood-derived DNA.  
 
Unlike the Affymetrix platform, the Illumina platform permits multiple samples to be 
genotyped per chip, depending on the chip design. Illumina fixed content genome 
wide association study SNP chips vary from single sample designs to duo designs, 
like the chip used for this study, up to designs which can assay 12 samples 
simultaneously on a single chip. This study was not designed to investigate the 
influence of array design, and there is as yet no published evidence to indicate that 
this is likely to be a significant factor in genotyping quality. 
 
Finally, including all consumables and labour costs each saliva sample used in this 
study cost on average USD$80 to collect and process. Here we have shown that saliva 
DNA is high quality and suitable as a template for array-based SNP genotyping, at 
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least for the Illumina Infinium genotyping platform. The Oragen kit also enables self-
collection and therefore presents minimal inconvenience to the participant, resulting 
in high response rates. Further, we have demonstrated that saliva samples can be sent 
in the mail to a central collection point, thereby reducing transportation costs and the 
risk of duplication. These financial and logistical benefits will positively impact other 
genetic studies seeking to expand collections for future research. 
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FIGURE LEGENDS 
 
Figure 1. No-call rates for the GWAS by study centre  
No-call rates across all Australian and New Zealand samples (N=1925), which passed 
the initial 98%, call rate threshold. Call rates are coloured according to study centre. 
The New Zealand samples (black) are all saliva derived DNAs. All Australian 
samples are from blood derived DNA. The black line is the median overall no-call 
rate (0.0019). Samples are plotted (when possible) according to ID number. Not all 
study centres have numerical IDs. 
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Figure 1 No-call rates for the GWAS by study centre 
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SUPPLEMENTARY FIGURES 
Supplementary Figures 1-5  
Scatter plots of GCScores of the ten blood saliva paired sample comparisons using all 
SNPs that passed QC. Sample 10 was excluded from the statistical analysis since the 
blood sample failed QC but is displayed here for comparison. 
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Supplementary Figure 1 GCScores for paired saliva blood DNA samples 1 and 2 
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Supplementary Figure 2 GCScores for paired saliva blood DNA samples 3 and 4 
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Supplementary Figure 3 GCScores for paired saliva blood DNA samples 5 and 6 
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Supplementary Figure 4 GCScores for paired saliva blood DNA samples 7 and 8 
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Supplementary Figure 5 GCScores for paired saliva blood DNA samples 9 and 
10 
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SUPPLEMENTARY TABLES 
Supplementary Table 1 DNA storage and extraction by study centre 
Description of storage time, time to extraction, and DNA extraction method for each 
study centre. 
 
Supplementary Table 2 Quartiles of no-call rates for study/centres in the MS 
GWAS. 
Quartiles for N=1925 samples that passed genotyping QC (no-call rate <0.02) 
calculated by study centre and DNA source. All/blood is the summary across all Aus 
centres. IQR is the Interquartile range and represents the range of no-call rates 
between the third and first quartiles.  
 
Supplementary Table 3 Mean quartiles and IQR of GCScores by study/centre 
and DNA source.  
Mean quartiles for N=1925 samples that passed genotyping QC (no-call rate <0.02) 
calculated by study centre and DNA source. All/blood is the summary across all Aus 
centres. IQR is the Interquartile range and represents the range of GCScores between 
the third and first quartiles.
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Supplementary Table 1 DNA storage and extraction by study centre  
Study centre N (% of Total) DNA source1 Age of 
blood/saliva 
DNA extraction 
method2 
Time to 
extraction 
Blood storage method3 
NZ/saliva 399 (20.7) Saliva <1 yr Oragene 1-2 months NR* 
Aus1/blood  12 (0.6) Mainly PB > 4 years Qiagen, salting out 3-4 years EDTA 
Aus2/blood  72 (3.7) PB <3 years Salting out 2-3 months EDTA 
Aus3/blood  126 (6.6) Mainly PB > 4 years Qiagen, salting out  3-4 years EDTA 
Aus4/blood 31 (1.6) PB <1 year Nucleon < 1 month EDTA 
Aus5/blood 326 (16.9) PB 2-8 years Salting out < 1 month EDTA 
Aus6/blood 115 (6.0) PB < 10 years Nucleon < 2 years EDTA 
Aus7/blood 67 (3.5) PB 4 years Nucleon 2-4 months EDTA 
Aus8/blood 125 (6.5) PB < 2 years Roche < 1 month EDTA 
Aus9/blood 646 (33.6) PB 5-7 years Phenol-Chloroform, 
Nucleon 
< 1year EDTA 
 10 
Aus10/blood 6 (0.3) PB 1.5 years Qiagen < 1 year ACD 
* NR = not relevant, 1 PB = peripheral blood, mainly PB = mainly peripheral blood with some cell lines, 2 Qiagen, Roche and Nucleon kits used 
as per manufacturer’s instructions, 3 EDTA = Ethylenediaminetetraacetic Acid, ACD = acid citrate dextrose 
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Supplementary Table 2 Quartiles of no-call rates for study centres in the MS 
GWAS 
 
Study centre N (% of 
Total) 
Median 1st Quartile 3rd Quartile IQR 
NZ/saliva 399 (21) 0.0024 0.002 0.0032 0.0012 
Aus1/blood 12 (0.6) 0.005 0.0047 0.005 0.0003 
Aus2/blood 72 (3.7) 0.0021 0.0018 0.0027 0.0009 
Aus3/blood 126 (6.6) 0.0042 0.0034 0.0073 0.0039 
Aus4/blood 31 (1.6) 0.0022 0.0018 0.0029 0.0011 
Aus5/blood 326 (16.9) 0.0018 0.0015 0.0025 0.001 
Aus6/blood 115 (6) 0.0017 0.0015 0.002 0.0005 
Aus7/blood 67 (3.5) 0.0017 0.0015 0.002 0.0005 
Aus8/blood 125 (6.5) 0.002 0.0016 0.0023 0.0007 
Aus9/blood 646 (33.6) 0.0016 0.0015 0.0018 0.0003 
Aus10/blood 6 (0.3) 0.0042 0.0039 0.0076 0.0037 
All blood 1526 (79.3) 0.0018 0.0015 0.0024 0.0009 
All 1925 (100) 0.0019 0.0016 0.0026 0.001 
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Supplementary Table 3 Mean Quartiles and IQR of GCScores by study centre 
and DNA source.  
 
Study centre N (% of 
Total) 
Median 1st Quartile 3rd Quartile IQR 
NZ/saliva 399 (20.7) 0.625 0.037 0.985 0.947 
Aus1/blood 12 (0.6) 0.617 0.046 0.984 0.938 
Aus2/blood 72 (3.7) 0.625 0.039 0.984 0.945 
Aus3/blood 126 (6.6) 0.625 0.037 0.985 0.945 
Aus4/blood 31 (1.6) 0.615 0.037 0.983 0.946 
Aus5/blood 326 (16.9) 0.618 0.039 0.984 0.945 
Aus6/blood 115 (6.0) 0.619 0.036 0.985 0.949 
Aus7/blood 67 (3.5) 0.618 0.035 0.984 0.949 
Aus8/blood 125 (6.5) 0.616 0.038 0.984 0.946 
Aus9/blood 646 (33.6) 0.618 0.036 0.986 0.950 
Aus10/blood 6 (0.3) 0.621 0.053 0.982 0.930 
All blood 1526 (79.1) 0.619 0.037 0.985 0.947 
All 1925 (100) 0.620 0.036 0.985 0.949 
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